Global Pharmatech Entered Research Agreement With Kobayashi Pharmaceutical Co., Ltd.

Published: Apr 18, 2006

JILIN, China, April 18 /Xinhua-PRNewswire/ -- Global Pharmatech, Inc. announced today that the R&D Director of Kobayashi Pharmaceutical Co., Ltd, Mr. Yoshihiro Yamaguchi, recently completed a trip to Natural Pharmatech (Jilin) Co., Ltd, a wholly-owned subsidiary of Global Pharmatech. Mr. Yoshihiro and his team inspected preclinical pharmacology and toxicology facilities and programs of Natural Pharmatech. Mr. Yoshihiro praised both the research equipment and experienced scientists and signed a new research service contract with Natural Pharmatech. He also expressed interest in a long term collaboration with the Company.

Dr. Xiaobo Sun, President and CEO of Global Pharmatech said, "We are delighted with this contract, which represents another step forward in our continuous effort to expand the global reach of our research services. Currently Natural Pharmatech has research partnerships with research institutions and pharmaceutical companies in Hong Kong, Singapore, Malaysia and Indonesia."

About Global Pharmatech

Global Pharmatech, through its subsidiaries, develops, manufactures and markets proprietary drugs that are based on Traditional Chinese Medicine using modern facilities and advanced R&D technologies. The company offers a full range of start-to-finish biotech services, from research and testing to manufacture and sale of liquid and solid dose products. The Company employs unique proprietary extraction methods and also licenses patents and technologies for botanical/biological drug products. Global Pharmatech's operations are currently based in the People's Republic of China with sales distribution centers in China, Malaysia, Singapore and Indonesia. For more information, please visit

About Kobayashi Pharmaceutical

Kobayashi Pharmaceutical , located in Osaka, Japan, was established in 1919. Kobayashi has 1101 employees and 28 subsidiaries, including 17 in Japan, 6 in the US, 1 in the UK and 3 in Asia. The management policy has always been to provide people and society with wonderful comfort through "creativity and innovation." Over the years, the Company has expanded its scope, developing into a cluster of enterprises with three principal businesses: Consumer Products Operation, Wholesale Operation and Medical Devices Operation. Its operations also include medical research and the distribution of dietary supplements. In the fiscal year ended March 31, 2005, Kobayashi achieved increases in sales and profits for the seventh consecutive year since the introduction of consolidated accounting. For more information, please visit

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to successfully develop and commercialize products, competitive products in our key markets, changes in consumer demand for our products, legislative, regulatory and competitive developments and general economic conditions. Our SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

Contact: Zhuojun Li Investor Relations Global Pharmatech, Inc. Tel: (905)787-8225 Fax: (905)787-9711 Email:

Global Pharmatech, Inc.

CONTACT: Zhuojun Li, Investor Relations, Global Pharmatech, Inc.,+1-905-787-8225, Fax: +1-905-787-9711,

Back to news